Prognostic Impact of Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma: Data from a Large Population-Based Database
23 February 2021
Purpose: Cytoreductive nephrectomy (CN) was considered a well-established treatment modality for patients with metastatic renal cell carcinoma (RCC) in the interferon era. However, its role after the introduction of multiple targeted therapies is less well established. Herein, We evaluated the effect of CN on overall survival (OS) on patients with RCC who were identified through the Surveillance, Epidemiology, and End Results database (SEER).
Materials and Methods: A total of 5,483 patients with metastatic RCC were identified from 2010 to 2016 using the SEER database. Factors pertaining to the following variables were collected: presence or absence of CN; age; gender; grade; status of metastasis to bone, liver, lung and brain; tumor stage; nodal status; histological subtypes; and chemotherapy status. Subjects who had CN were matched with those who did not in all previously mentioned covariates using inverse probability weighting. These weights were then used in adjusted Cox regression models to report doubly robust estimates.
Results: CN was associated with 67% reduction in the hazards of death. Advanced T-stage, N1 disease, advanced tumor grade, non-clear histology and metastasis to bone, liver, lung or brain are independent risk factors for death. Patients with T4 disease benefited less of CN compared to those with T1 disease, while higher number of metastatic sites didn’t predict worse outcome among those who had CN.
Conclusion: CN could provide a survival advantage in favorable risk patients with RCC in the era of targeted therapy.
- Cytoreductive nephrectomy
- Metastatic renal cell carcinoma
- Clear cell renal cell carcinoma
How to Cite
Bex, A. et al. (2019) ‘Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.’, JAMA oncology, 5(2), pp. 164–170. doi: 10.1001/jamaoncol.2018.5543.
Cao, D. et al. (2019) ‘Adverse Effect of Lymph Node Dissection in Metastatic Renal Cell Cancer Patients Treated with Cytoreductive Nephrectomy: A Contemporary Analysis of Survival.’, Journal of Cancer, 10(19), pp. 4639–4646. doi: 10.7150/jca.33923.
Fallick, M. L. et al. (1997) ‘Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.’, The Journal of urology. United States, 158(5), pp. 1691–1695. doi: 10.1016/s0022-5347(01)64097-7.
Flanigan, R. C. et al. (2001) ‘Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer’, New England Journal of Medicine. doi: 10.1056/NEJMoa003013.
Graham, J., Bhindi, B. and Heng, D. Y. C. (2019) ‘The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.’, Current opinion in urology. United States, 29(5), pp. 507–512. doi: 10.1097/MOU.0000000000000657.
Heng, D. Y. C. et al. (2014) ‘Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.’, European urology. Switzerland, 66(4), pp. 704–710. doi: 10.1016/j.eururo.2014.05.034.
Méjean, A. et al. (2018) ‘Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.’, The New England journal of medicine. United States, 379(5), pp. 417–427. doi: 10.1056/NEJMoa1803675.
Mickisch, G. H. J. et al. (2001) ‘Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial’, Lancet. doi: 10.1016/S0140-6736(01)06103-7.
Motzer, R. J. et al. (2007) ‘Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.’, The New England journal of medicine. United States, 356(2), pp. 115–124. doi: 10.1056/NEJMoa065044.
Motzer, R. J. et al. (2009) ‘Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.’, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(22), pp. 3584–3590. doi: 10.1200/JCO.2008.20.1293.
Motzer, R. J. and Russo, P. (2018) ‘Cytoreductive Nephrectomy - Patient Selection Is Key.’, The New England journal of medicine. United States, pp. 481–482. doi: 10.1056/NEJMe1806331.
Petejova, N. and Martinek, A. (2016) ‘Renal cell carcinoma: Review of etiology, pathophysiology and risk factors.’, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. Czech Republic, 160(2), pp. 183–194. doi: 10.5507/bp.2015.050.
Thoenes, W., Störkel, S. and Rumpelt, H. J. (1986) ‘Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.’, Pathology, research and practice. Germany, 181(2), pp. 125–143. doi: 10.1016/S0344-0338(86)80001-2.
Vaishampayan, U., George, J. and Vigneau, F. (2019) ‘Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases.’, Journal of kidney cancer and VHL, 6(1), pp. 13–25. doi: 10.15586/jkcvhl.2019.121.
- Abstract Viewed: 0 times
- Just Accepted/6593 Downloaded: 0 times